JPWO2021011903A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021011903A5 JPWO2021011903A5 JP2022503450A JP2022503450A JPWO2021011903A5 JP WO2021011903 A5 JPWO2021011903 A5 JP WO2021011903A5 JP 2022503450 A JP2022503450 A JP 2022503450A JP 2022503450 A JP2022503450 A JP 2022503450A JP WO2021011903 A5 JPWO2021011903 A5 JP WO2021011903A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- fragment
- antibody
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962875309P | 2019-07-17 | 2019-07-17 | |
| US62/875,309 | 2019-07-17 | ||
| PCT/US2020/042627 WO2021011903A1 (en) | 2019-07-17 | 2020-07-17 | Factor h potentiating antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022541275A JP2022541275A (ja) | 2022-09-22 |
| JPWO2021011903A5 true JPWO2021011903A5 (es) | 2023-07-19 |
Family
ID=74211270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022503450A Pending JP2022541275A (ja) | 2019-07-17 | 2020-07-17 | Ｈ因子増強性抗体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11820814B2 (es) |
| EP (1) | EP3999073A4 (es) |
| JP (1) | JP2022541275A (es) |
| KR (1) | KR20220057530A (es) |
| CN (1) | CN114828886A (es) |
| AR (1) | AR122286A1 (es) |
| AU (1) | AU2020313981A1 (es) |
| BR (1) | BR112022000739A2 (es) |
| CA (1) | CA3147638A1 (es) |
| IL (1) | IL289812A (es) |
| MX (1) | MX2022000725A (es) |
| TW (1) | TW202110893A (es) |
| WO (1) | WO2021011903A1 (es) |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO2003080672A1 (en) | 2002-03-22 | 2003-10-02 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| US20090004183A1 (en) | 2004-07-23 | 2009-01-01 | Taylor Ronald P | Compositions and Methods for Regulating the Alternative Pathway of Complement |
| KR20170002684A (ko) | 2005-11-04 | 2017-01-06 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
| FR2894145B1 (fr) | 2005-12-07 | 2008-10-17 | Lab Francais Du Fractionnement | Utilisation de facteur h du complement a titre de medicament |
| KR20150029002A (ko) | 2007-06-07 | 2015-03-17 | 제넨테크, 인크. | 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법 |
| GB0819633D0 (en) | 2008-10-25 | 2008-12-03 | Isis Innovation | Composition |
| JP2013508287A (ja) | 2009-10-14 | 2013-03-07 | ヤンセン バイオテツク，インコーポレーテツド | 抗体を親和性成熟する方法 |
| CA2780221A1 (en) | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
| US9295713B2 (en) | 2010-09-15 | 2016-03-29 | Celldex Therapeutics, Inc. | Treatment of chronic nephropathies using soluble complement receptor type I (sCR1) |
| WO2013078223A1 (en) * | 2011-11-23 | 2013-05-30 | Children's Hospital & Research Center Oakland | Anti-factor h binding protein antibodies and methods of use thereof |
| US9926366B2 (en) | 2012-10-04 | 2018-03-27 | Novelmed Therapeutics, Inc. | Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies |
| GB201318170D0 (en) * | 2013-10-14 | 2013-11-27 | Univ Edinburgh | Proteins with Diagnostic and Therapeutic Uses |
| EP3066132A2 (en) | 2013-11-07 | 2016-09-14 | Novo Nordisk A/S | Novel methods and antibodies for treating coagulapathy |
| US10357554B2 (en) | 2013-11-11 | 2019-07-23 | The United States Of America, As Represented By The Secretary Of The Army | AMA-1 epitopes, antibodies, compositions, and methods of making and using the same |
| CN107074939B (zh) | 2014-08-20 | 2021-09-07 | 桑昆血液供给基金会 | H因子增强抗体及其用途 |
| BR112017003582B1 (pt) | 2014-08-27 | 2024-01-09 | Memorial Sloan Kettering Cancer Center | Agente de anticorpo, uso do mesmo, composição farmacêutica e receptor de antígeno quimérico |
| WO2017114401A1 (zh) * | 2015-12-31 | 2017-07-06 | 江苏匡亚生物医药科技有限公司 | 具有补体调节活性的重组补体因子h-免疫球蛋白融合蛋白及其制备方法与应用 |
| CR20180529A (es) * | 2016-04-04 | 2019-03-21 | Bioverativ Usa Inc | Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada |
| GB201608046D0 (en) * | 2016-05-09 | 2016-06-22 | Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The | Treatment of complement-mediated disorders |
| US20190202878A1 (en) * | 2016-06-28 | 2019-07-04 | Universitat Ulm | Complement inhibitors and uses thereof |
| US10865238B1 (en) * | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
| KR20200110688A (ko) * | 2018-01-15 | 2020-09-24 | 스티흐팅 산퀸 불드포르지닝 | 인자 h 강화 항체 및 이의 사용 |
-
2020
- 2020-07-17 AR ARP200102011A patent/AR122286A1/es unknown
- 2020-07-17 AU AU2020313981A patent/AU2020313981A1/en active Pending
- 2020-07-17 KR KR1020227005261A patent/KR20220057530A/ko unknown
- 2020-07-17 CA CA3147638A patent/CA3147638A1/en active Pending
- 2020-07-17 EP EP20840846.8A patent/EP3999073A4/en active Pending
- 2020-07-17 JP JP2022503450A patent/JP2022541275A/ja active Pending
- 2020-07-17 MX MX2022000725A patent/MX2022000725A/es unknown
- 2020-07-17 WO PCT/US2020/042627 patent/WO2021011903A1/en unknown
- 2020-07-17 BR BR112022000739A patent/BR112022000739A2/pt unknown
- 2020-07-17 TW TW109124345A patent/TW202110893A/zh unknown
- 2020-07-17 CN CN202080063736.7A patent/CN114828886A/zh active Pending
- 2020-07-17 US US17/627,503 patent/US11820814B2/en active Active
-
2022
- 2022-01-12 IL IL289812A patent/IL289812A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200172605A1 (en) | Gene therapy for alzheimer's and other neurodegenerative diseases and conditions | |
| US10875910B2 (en) | Antibodies recognizing alpha-synuclein | |
| JP2019527543A5 (es) | ||
| JP6342333B2 (ja) | α−シヌクレインを認識するヒト化抗体 | |
| JP2010538608A5 (es) | ||
| JP2019527194A5 (es) | ||
| RU2009128064A (ru) | Антитела к cd44 | |
| JP7410522B2 (ja) | 抗ｆａｍ１９ａ５抗体のアデノ関連ウイルス（ａａｖ）伝達 | |
| JP2020536532A5 (es) | ||
| WO2014052693A2 (en) | Veterinary composition and methods for non-surgical neutering and castration | |
| JP2019511911A5 (es) | ||
| JP2023089191A5 (es) | ||
| JP2021510523A5 (es) | ||
| WO2020160337A1 (en) | Systems for evolved adeno-associated viruses (aavs) for targeted delivery | |
| CN113354730B (zh) | 一种抗新型冠状病毒的单克隆抗体及其应用 | |
| EP3253792A1 (en) | Anti-tau constructs | |
| US20160355581A1 (en) | Compositions and methods for treating amyloid plaque associated symptoms | |
| RU2018131123A (ru) | Антитела к tgf-бета2 | |
| CN110540590A (zh) | 一种自免疫抑制物的开发和应用 | |
| BRPI0612734A2 (pt) | anticorpo monoclonal, composição farmacêutica, métodos de promoção de brotamento axonal, e de produção de um anticorpo anti-nogo, e, uso de um anticorpo anti-nogo | |
| JPWO2021011903A5 (es) | ||
| JP2019514343A5 (es) | ||
| JP2023522212A (ja) | 治療用ｍｕｓｋ抗体 | |
| RU2380377C2 (ru) | Nogo-A-СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ | |
| RU2022103907A (ru) | Антитела, активирующие фактор н, и их применение |